Status:
COMPLETED
Convalescent Plasma for COVID-19 Patients
Lead Sponsor:
Vinmec Research Institute of Stem Cell and Gene Technology
Collaborating Sponsors:
National Institute of Hygiene and Epidemiology, Vietnam
National Hospital for Tropical Diseases, Hanoi, Vietnam
Conditions:
COVID 19
Eligibility:
All Genders
18-75 years
Phase:
EARLY_PHASE1
Brief Summary
The investigators propose to evaluate intravenous administration of convalescent plasma (CP) obtained from COVID19 survivors in COVID19 patients who are in the medium stage. Supportive data exist for ...
Detailed Description
Coronaviruses are among the most common causes of the common cold in humans.1,2 In recent decades, coronavirus has caused several epidemic worldwide with a vast number of deaths such as severe acute r...
Eligibility Criteria
Inclusion
- Age 18-75 years
- SARS-CoV-19 PCR positive
- Medium stage
- Time from onset to screening ≤ 21 days, the SARS-CoV-2 test is still positive
Exclusion
- Patients with a history of autoimmune disease or IgA deficiency
- Patients with a history of allergy
- Multi-organ/system failure
- Pregnant or breastfeeding at the time of study
- Cancer, history of heart failure, stroke, bronchial asthma
- Multi-organ/system failure with indications for dialysis, severe hypoxia, failure with conventional treatment methods, indications for ECMO.
- The patient is infected with multidrug-resistant bacteria.
- The patient is participating in another study.
- Time from onset to screening\> 21 days
Key Trial Info
Start Date :
August 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2021
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT04516954
Start Date
August 1 2020
End Date
April 30 2021
Last Update
June 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vinmec Research Institute of Stem cell and Gene Technology
Hanoi, Vietnam, 10000